IEQ Capital’s Esperion Therapeutics ESPR Stock Holding History

IEQ Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,882	Closed	-$36.8K	–	1903
2025 Q3	$36.8K	Buy	13,882 +1,381	+11%	+$2.67K	﹤0.01%	1809
2025 Q2	$12.3K	Buy	+12,501	New	+$12.5K	﹤0.01%	1805

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IEQ Capital's ESPR Position: Q4 2025 in Review

IEQ Capital sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 13,882 shares — an estimated $36.8K sold.

IEQ Capital first reported a position in ESPR in Q2 2025 and held it in 2 quarters. The position peaked at $36.8K in Q3 2025. 201 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

IEQ Capital reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
IEQ Capital sold 13,882 Esperion Therapeutics shares in Q4 2025, an estimated $36.8K.
IEQ Capital first reported a position in Esperion Therapeutics in Q2 2025 and held it in 2 quarters.
IEQ Capital's Esperion Therapeutics position peaked at $36.8K in Q3 2025.
201 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on IEQ Capital's 13F filing for Q4 2025, filed 13 Feb 2026.